img_hblbg.jpg
logo.jpg
img_hbrbg.jpg
Home > R & D - Formulations
img_blueB.jpg

R & D

RnD.jpg

img_blueB.jpg
img_inp_rblbg.jpg

Latest @ Ipca

Ipca - Ratlam formulations plant ranked third position in the National Energy Conservation Award - 2010.

img_inp_rblbg.jpg

Formulations

Formulation Development
Our Formulation Development Laboratory located at Mumbai has been gearing up for a state-of-the-art R & D facility (in line with the US-FDA requirements). The current R & D activities are also approved by the Department of Science and Technology, Government of India. The laboratory is well equipped with various ultramodern equipments and technologies required for conducting high quality research activities and prototype equipments as that of manufacturing facilities.

Infrastructures in the R & D:

  • Formulations

    - High Sheer Mixer (GMP model)

    - Fluid Bed Drier

    - Fluid Bed Processor

    - Ganscoata

    - Walk-in Stability Chambers

    - Dissolution Apparatus with Intrinsic Dissolution Assembly

    - Bilayer Tablet Compression Machine

    - Hard Gel Capsule Facility

    - Blister Packing Machine with Alu-Alu Facility

    - Press-Cota

    - Roll Compactor

    - Pelletisation Facility

    - Compression of Pellets (MUPS Tablet)

    - Facility for Effervescent tablets (Low RH Area)

    - Reverse Laminar flow

  • Analyticals

    - Gas Chromatography Equipment (GC)

    -  High Performance Liquid Chromatography(HPLC)

    -  High Performance Thin Layer Chromatography (HPTLC)

    -  Malvern Particle Size Analyzer

    -  FTIR

The key activities of R & D-Formulations are:

  • Novel Drug Delivery System (NDDS)
    R & D in this area attempts to improve the efficiency with which the medicine is absorbed in the body. Novel Drug Delivery Systems (NDDS) efforts are directed towards:

1. Controlled Release
Ipca Research concentrates on sustained, delayed and pulsatile release. The company introduced a novel bilayer tablet for an antidiabetic combination.

2. Novel Dosage Formulations
In the novel dosage form, the company concentrates on the following therapeutic segments.

- Cardiac Care
- Antiinfectives
- Antidiabetics
- Anti depressants
- Anti inflammatory
- Antimalarials

Ipca R & D laboratory has filed patents across the world for products based on the NDDS. Ipca strength in this segment of R & D puts the company in an excellent position to compete in the growing markets for generic drugs in Europe and USA.

  • Abbreviated New Drug Application (ANDA)
    The filing of ANDAs received a major boost after Ipca opened its wholly owned subsidiary in New Jersey, USA. The company will now be working on ANDAs to address the growing opportunity in USA. Ipca research endeavors are well supported by worldclass infrastructure comprising:

- Analytical Research
- Clinical Research
- International Regulatory Affairs
- Corporate Quality Assurance
- Intellectual Property Cell

  • Manufacturing of generic products for registration in UK/EU/South Africa/Brazil and many other countries
  • The Formulation R & D Capability includes
    - Design and development of new dosage forms
    - Pre formulation studies
    - Lab / pilot scale studies
    - Process optimization/validation studies
    - Stability studies as per ICH guidance
    - Technology transfer of new products
    - Technical supports to manufacturing location
    - Technology and latest development up gradation to provide technically superior, process efficient and International
    standards product.

The group is well supported by analytical development team which is committed for development of analytical methodologies that provide sensitive, precise, rugged & accurate data in minimum time. Key activities include development & validation of various analytical test procedures for Assay, Content Uniformity, Dissolution, Related Substances, Residual Solvents, other in-house test procedures & finalization of their Specifications which will adequately evaluate desire quality attributes.

Copyright © Ipca Laboratories Ltd. 2012. All Rights Reserved.